Los Angeles, CA. March 17,
2020 – The next chapter in US Nuclear’s (OTC: UCLE) brain-machine interface
revolution is treating Parkinson’s Disease.
Over 10 million people live with Parkinson’s Disease worldwide. Parkinson’s Disease is a degenerative,
progressive nervous system disorder that affects nerve cells in deep parts of
the brain that control movement and memory.
These nerve cells become impaired and/or die, thereby producing less
dopamine thus ultimately causing the symptoms of Parkinson’s Disease. These symptoms include: tremors or shaking in
your limbs, slowed movement, rigid muscles, impaired balance, coordination, and
eventually, profound memory loss and dementia.
Fortunately, advances in neurostimulation therapy, such as those made by
Grapheton, have made it possible to treat this terrible disease.
The treatment is called ‘Deep Brain Stimulation’ (DBS) and
involves the surgical implantation of electrodes in your brain that send
electrical signals to the areas responsible for body movement. The electrodes do not damage healthy brain
tissue or destroy nerve cells; instead they produce electrical impulses that
regulate the abnormal impulses, including those caused by Parkinson’s.
A short video made by University Hospitals on treating Parkinson’s
Disease using Deep Brain Stimulation can be viewed here: https://www.youtube.com/watch?v=MDTkuCDQU_4
Grapheton has pushed the development of neurostimulation probes
even further. Current implantable neural
probes for DBS have electrodes that do not last longer than few years and
batteries that will deplete over time, therefore requiring repeat cranial surgeries
that are expensive, inconvenient, and risky.
Current systems also only record electrical signals from the brain and
provide a limited window into the complex electrical and chemical interactions
at the areas of treatment which can cause side effects.
Grapheton has solved these issues by:
1.
Creating a new carbon-based
electrode that doesn’t corrode and can last as long as 40 years or more,
thereby greatly reducing the surgery required for maintenance.
2.
Creating a new self-charging
battery that uses the brain’s own salty liquid environment as the power source,
negating the need for battery replacement/maintenance.
3.
Two-way electrical and chemical
communication with brain neurons which allows more effective, tailored, and
on-demand electrical stimulation, and eliminates most of the current
side-effects thus allowing treatment of a wider variety of patients.
Grapheton will provide the neurostimulation probes while US
Nuclear provides the ancillary equipment for processing the electrical signals
and data.
Safe Harbor Act
This press release includes "forward-looking statements"
within the meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. Actual results may differ from
expectations, estimates and projections and, consequently, you should not rely
on these forward looking statements as predictions of future events. Words such
as "expect," "estimate," "project,"
"budget," "forecast," "anticipate,"
"intend," "plan," "may," "will,"
"could," "should," "believes,"
"predicts," "potential," "continue," and similar
expressions are intended to identify such forward-looking statements. These
forward-looking statements involve significant risks and uncertainties that
could cause the actual results to differ materially from the expected results.
Investors may find additional information regarding US Nuclear Corp. at
the SEC website at http://www.sec.gov, or the company’s website at
www.usnuclearcorp.com
CONTACT:
US
Nuclear Corp. (OTCBB: UCLE)
Robert
I. Goldstein, President, CEO, and Chairman
Rachel
Boulds, Chief Financial Officer
(818)
883 7043
Email:
info@usnuclearcorp.com
Comments
Post a Comment